Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diagnosing Natriuretic Peptide Deficiency Pilot
NCT03035929Phase 1Completed
- Sponsor
- Vanderbilt University Medical Center
- Start
- Jan 2017
- Primary completion
- Jun 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dexamethasone in Natriuretic peptide deficiency, sponsored by Vanderbilt University Medical Center. Primary endpoints: Change in N-terminal pro-atrial natriuretic peptide at 8 hours and Change in N-terminal pro-B-type natriuretic peptide at 8 hours. Started Jan 2017; status: completed.
02
Drugs
dexamethasone
03
Conditions
Natriuretic peptide deficiency
Beyond the preview
Go deeper on NCT03035929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03035929.